Loading...
XETR
AFX
Market cap2.93bUSD
Jul 10, Last price  
30.60EUR
1D
4.51%
1Q
17.96%
Jan 2017
-12.57%
IPO
19.77%
Name

Carl Zeiss Meditec AG

Chart & Performance

D1W1MN
XETR:AFX chart
P/E
18.97
P/S
1.20
EPS
1.61
Div Yield, %
2.05%
Shrs. gr., 5y
-0.43%
Rev. gr., 5y
10.78%
Revenues
2.23b
+7.82%
390,563,000569,695,000600,190,000640,089,000676,682,000758,793,000861,875,000906,445,000909,255,0001,040,061,0001,088,365,0001,189,896,0001,280,860,0001,459,321,0001,335,452,0001,646,785,0001,902,836,0002,089,300,0002,066,127,0002,227,645,000
Net income
141m
-20.99%
26,688,00049,646,00056,241,00055,101,00059,596,00066,906,00071,870,00092,131,00074,954,00062,297,00098,330,000134,445,000126,463,000159,756,000122,385,000236,276,000293,909,000290,396,000178,726,000141,210,000
CFO
210m
-15.15%
55,509,00056,079,00054,872,00087,356,00065,211,00037,545,00092,100,00064,624,00063,105,00056,744,000111,770,00037,732,000187,207,000219,634,000178,527,000362,663,000188,199,000250,861,000247,319,000209,858,000
Dividend
Mar 27, 20260.55 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Carl Zeiss Meditec AG functions as a prominent global medical technology firm, conducting its operations across Germany, other European nations, the United States, and various Asian markets. Its business is organized into two principal divisions: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment provides an array of products and solutions tailored for the diagnosis and therapeutic management of ocular conditions, including specialized systems and essential consumables for cataract, retinal, and refractive surgical procedures. This division serves ophthalmologists, optometrists, and medical and surgical professionals in hospitals and ambulatory surgery centers. The Microsurgery segment focuses on delivering advanced visualization tools vital for intricate surgical interventions, additionally supplying specialized solutions for ear, nose, and throat (ENT), plastic and reconstructive, dental, and spinal surgeries. This segment supports a diverse group of medical practitioners across various disciplines, as well as healthcare institutions. Established in 1846 and headquartered in Jena, Germany, the company operates as a subsidiary of Carl Zeiss AG.
IPO date
Mar 20, 2000
Employees
4,224
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT